EFS: Value to Innovation

Rick Geoffrion
President & CEO, Mitralign, Inc.
March 6th, 2019
What was the Pathway for a Class III Device 7 Years Ago?

- FIM Outside the US, maybe outside EU
- Pre-CE Mark Study in the EU
- CE Mark Study in EU
- Use CE Mark data (partial or complete) to start a Feasibility Study in the US
- Commercialize in EU to financially support US pivotal
- US Pivotal Trial
What was the Impact of the Pathway that existed 7 years ago?

• In the US, access to new medical technologies lagged the EU by more than 4 years

• Cutting edge medical device research all but left the US in search of a faster pathway for clinical research and market approval.

• Investment money left the medical device space in search of technologies that could make it to market faster and more predictably.
EFS Arrived at the Most Opportune Time for MedTech

• Implant scandal in Europe has resulted tighter regulations.

• Germany has transitioned from a decentralized system to a centralized one..... Effectively shut down to early stage studies.

• Without EFS, there would be no reputable outlet for early stage investigation.

• Many Class III technologies would have ceased to exist.
Benefits of the EFS Program: Value to Innovation

• Early access to reputable clinical sites
• Faster time to the single largest market in the world
• If company is based in the US, significant savings in travel cost and resource dilution
• Bring the FDA and CMS up to speed earlier, injecting more predictability into the future regulatory pathway
Benefits of the EFS Program: Value to Innovation

• Accelerate overall timeline to market by leveraging US cases into the CE Mark pathway
  • No need to forsake the EU in favor of the US
  • Once the design is stable, US cases may be credited towards the CE Mark to accelerate approval times
  • Concept can apply to certain other countries as well
Trialign Case Study: FDA EFS IDE Approval Timeline

A huge step forward on the front end, a lot of work to be completed on the back end
EFS: Value to US Innovation
The New Paradigm - When to Come to the US

• US Early Feasibility Study (EFS)
  o Could be your FIM (10—15 pts)
• US Extended Feasibility & CE Mark Combination
• US Pivotal Trial

Bottom Line: The US has once again become the place for early stage clinical research